Tallahassee Journal

Relapsed/Refractory Acute Myeloid Leukemia Overview

Relapsed/Refractory Acute Myeloid Leukemia Myeloid Leukemia which means the leukemia has come back after treatment and remission. Refractory AML means the leukemia did not respond to treatment. AML relapse affects about 50% of all patients who achieved remission after initial treatment, and can occur several months to several years after treatment. Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor prognosis and treatment remains challenging.

“Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Relapsed/Refractory Acute Myeloid Leukemia Market. 

The Relapsed/Refractory Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Relapsed/Refractory Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years. Relapsed/Refractory Acute Myeloid Leukemia Key players such as – Celyad Oncology, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, GlycoMimetics, AROG Pharmaceuticals, and others, are developing therapies for the Relapsed/Refractory Acute Myeloid Leukemia treatment 

• Relapsed/Refractory Acute Myeloid Leukemia Emerging therapies such as – CYAD-02, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others are expected to have a significant impact on the Relapsed/Refractory Acute Myeloid Leukemia market in the coming years.  
• In June 2016 GlycoMimetics, Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-select in antagonist GMI-1271 for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and elderly patients aged 60 years or older with AML
• In October 2021 Apollomics initiated a Phase III randomized, double-blinded bridging trial to evaluate the efficacy of Uproleselan administered with chemotherapy versus chemotherapy alone in chinese patients with Relapsed/Refractory Acute Myeloid Leukemia  

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics Assessment

• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Product Type
• Relapsed/Refractory Acute Myeloid Leukemia By Stage and Product Type
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Route of Administration
• Relapsed/Refractory Acute Myeloid Leukemia By Stage and Route of Administration
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Molecule Type
• Relapsed/Refractory Acute Myeloid Leukemia by Stage and Molecule Type

DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Relapsed/Refractory Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include: 

• CYAD-02: Celyad Oncology
• FHD-286: Foghorn Therapeutics
• AB8939: AB Science
• ONC201: Oncoceutics
• Sarclisa: Sanofi
• TCB008: TC Biopharm
• Keytruda: Merck & Co
• Uproleselan: GlycoMimetics
• Crenolanib: AROG Pharmaceuticals 

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis:

The Relapsed/Refractory Acute Myeloid Leukemia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Relapsed/Refractory Acute Myeloid Leukemia treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsed/Refractory Acute Myeloid Leukemia Treatment.
• Relapsed/Refractory Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Relapsed/Refractory Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsed/Refractory Acute Myeloid Leukemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Relapsed/Refractory Acute Myeloid Leukemia product details are provided in the report. Download the Relapsed/Refractory Acute Myeloid Leukemia pipeline report to learn more about the emerging Relapsed/Refractory Acute Myeloid Leukemia therapies

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Drivers

• Rising incidence of Acute Myeloid Leukemia
• Advancements in pharmacology and molecular biology to promote drug development
• Rising geriatric population

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Barriers

• High cost associated with the management of Acute Myeloid Leukemia
• Side effects associated with the Acute Myeloid Leukemia treatment

Get a Free Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia Pipeline Assessment

Scope of Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drug Insight    

• Coverage: Global
• Key Relapsed/Refractory Acute Myeloid Leukemia Companies: Celyad Oncology, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, GlycoMimetics, AROG Pharmaceuticals, and others
• Key Relapsed/Refractory Acute Myeloid Leukemia Therapies: CYAD-02, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment: Relapsed/Refractory Acute Myeloid Leukemia current marketed and Relapsed/Refractory Acute Myeloid Leukemia emerging therapies
• Relapsed/Refractory Acute Myeloid Leukemia Market Dynamics:  Relapsed/Refractory Acute Myeloid Leukemia market drivers and Relapsed/Refractory Acute Myeloid Leukemia market barriers 

Request for Sample PDF Report for Relapsed/Refractory Acute Myeloid Leukemia Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia drugs and therapies

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market